Nymox Pharmaceutical Corporation Stock Price, News & Analysis (NASDAQ:NYMX)

$3.73 0.03 (0.81 %)
(As of 11/18/2017 05:42 AM ET)
Previous Close$3.73
Today's Range$3.67 - $3.82
52-Week Range$2.67 - $5.10
Volume90,407 shs
Average Volume75,515 shs
Market Capitalization$202.92 million
P/E RatioN/A
Dividend YieldN/A
Beta0.82

About Nymox Pharmaceutical Corporation (NASDAQ:NYMX)

Nymox Pharmaceutical Corporation logoNymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also has a patent portfolio covering its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex conducts research and development, and manufacturing for NicAlert and TobacAlert.


Industry, Sector and Symbol:
  • Industry: Diagnostic Substances
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:NYMX
  • CUSIP: N/A
  • Web: www.nymox.com
Debt:
  • Debt-to-Equity Ratio: 61.64%
  • Current Ratio: 1.44%
  • Quick Ratio: 1.42%
Sales & Book Value:
  • Annual Sales: $280,000.00
  • Price / Sales: 724.69
  • Book Value: N/A
  • Price / Book: N/A
Profitability:
  • Trailing EPS: ($0.24)
  • Net Income: ($13,100,000.00)
  • Net Margins: -8,237.58%
  • Return on Assets: -753.01%
Misc:
  • Employees: 6
  • Outstanding Shares: 54,400,000
 

Frequently Asked Questions for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)

What is Nymox Pharmaceutical Corporation's stock symbol?

Nymox Pharmaceutical Corporation trades on the NASDAQ under the ticker symbol "NYMX."

How were Nymox Pharmaceutical Corporation's earnings last quarter?

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced its earnings results on Friday, November, 14th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter. The biopharmaceutical company had revenue of $0.08 million for the quarter. View Nymox Pharmaceutical Corporation's Earnings History.

When will Nymox Pharmaceutical Corporation make its next earnings announcement?

Nymox Pharmaceutical Corporation is scheduled to release their next quarterly earnings announcement on Tuesday, November, 21st 2017. View Earnings Estimates for Nymox Pharmaceutical Corporation.

Are investors shorting Nymox Pharmaceutical Corporation?

Nymox Pharmaceutical Corporation saw a decrease in short interest in the month of October. As of October 13th, there was short interest totalling 910,562 shares, a decrease of 22.8% from the September 29th total of 1,179,164 shares. Based on an average trading volume of 80,819 shares, the short-interest ratio is presently 11.3 days. Currently, 3.0% of the company's shares are sold short.

Who are some of Nymox Pharmaceutical Corporation's key competitors?

Who owns Nymox Pharmaceutical Corporation stock?

Nymox Pharmaceutical Corporation's stock is owned by a number of of retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (0.50%). View Institutional Ownership Trends for Nymox Pharmaceutical Corporation.

Who bought Nymox Pharmaceutical Corporation stock? Who is buying Nymox Pharmaceutical Corporation stock?

Nymox Pharmaceutical Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. View Insider Buying and Selling for Nymox Pharmaceutical Corporation.

How do I buy Nymox Pharmaceutical Corporation stock?

Shares of Nymox Pharmaceutical Corporation can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nymox Pharmaceutical Corporation's stock price today?

One share of Nymox Pharmaceutical Corporation stock can currently be purchased for approximately $3.73.

How big of a company is Nymox Pharmaceutical Corporation?

Nymox Pharmaceutical Corporation has a market capitalization of $202.92 million and generates $280,000.00 in revenue each year. The biopharmaceutical company earns ($13,100,000.00) in net income (profit) each year or ($0.24) on an earnings per share basis. Nymox Pharmaceutical Corporation employs 6 workers across the globe.

How can I contact Nymox Pharmaceutical Corporation?

Nymox Pharmaceutical Corporation's mailing address is 9900 CAVENDISH BLVD. SUITE 306, St.-Laurent A8, H4M 2V2. The biopharmaceutical company can be reached via phone at 800-936-9669 or via email at [email protected]


MarketBeat Community Rating for Nymox Pharmaceutical Corporation (NASDAQ NYMX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  41 (Vote Outperform)
Underperform Votes:  42 (Vote Underperform)
Total Votes:  83
MarketBeat's community ratings are surveys of what our community members think about Nymox Pharmaceutical Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)

Price Target History for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)

Analysts' Ratings History for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)

Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History and Estimates Chart for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)

Earnings by Quarter for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)

Earnings History by Quarter for Nymox Pharmaceutical Corporation (NASDAQ NYMX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/21/2017        
11/14/2014Q314($0.02)$0.08 millionViewN/AView Earnings Details
11/13/2013Q3($0.03)ViewN/AView Earnings Details
5/15/2013Q1 2013($0.05)($0.03)$0.78 million$0.18 millionViewN/AView Earnings Details
11/14/2012Q312($0.06)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Nymox Pharmaceutical Corporation (NASDAQ NYMX)

Insider Ownership Percentage: 54.00%
Institutional Ownership Percentage: 5.60%
Insider Trades by Quarter for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
Insider Trades by Quarter for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)

Insider Trades by Quarter for Nymox Pharmaceutical Corporation (NASDAQ NYMX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/3/2017James George RobinsonDirectorBuy10,000$3.73$37,300.00View SEC Filing  
8/2/2017James George RobinsonDirectorBuy5,000$3.79$18,950.00View SEC Filing  
8/1/2017James George RobinsonDirectorBuy15,000$3.72$55,800.00View SEC Filing  
7/7/2017James George RobinsonDirectorBuy11,500$4.00$46,000.00View SEC Filing  
7/6/2017James George RobinsonDirectorBuy3,000$3.92$11,760.00View SEC Filing  
7/5/2017James George RobinsonDirectorBuy5,000$3.97$19,850.00View SEC Filing  
6/28/2017James George RobinsonDirectorBuy8,500$4.09$34,765.00View SEC Filing  
6/26/2017James George RobinsonDirectorBuy15,000$3.80$57,000.00View SEC Filing  
6/21/2017James George RobinsonDirectorBuy15,000$3.77$56,550.00View SEC Filing  
6/20/2017James George RobinsonDirectorBuy5,000$3.76$18,800.00View SEC Filing  
6/19/2017James George RobinsonDirectorBuy5,000$3.79$18,950.00View SEC Filing  
5/30/2017James George RobinsonDirectorBuy54,500$3.81$207,645.00View SEC Filing  
3/8/2017James George RobinsonDirectorBuy50,000$3.59$179,500.00View SEC Filing  
8/10/2016James George RobinsonDirectorBuy500$2.47$1,235.00View SEC Filing  
8/4/2016James George RobinsonDirectorBuy7,000$3.41$23,870.00View SEC Filing  
7/29/2016James George RobinsonDirectorBuy22,500$3.86$86,850.00View SEC Filing  
7/20/2016James George RobinsonDirectorBuy10,000$3.33$33,300.00View SEC Filing  
7/7/2016James George RobinsonDirectorBuy20,000$3.28$65,600.00View SEC Filing  
6/29/2016James George RobinsonDirectorBuy17,500$3.53$61,775.00View SEC Filing  
6/24/2016James George RobinsonDirectorBuy22,500$2.97$66,825.00View SEC Filing  
5/13/2016James George RobinsonDirectorBuy28,010$2.31$64,703.10View SEC Filing  
5/3/2016James George RobinsonDirectorBuy6,990$2.36$16,496.40View SEC Filing  
4/29/2016James George RobinsonDirectorBuy15,000$2.27$34,050.00View SEC Filing  
4/15/2016James George RobinsonDirectorBuy39,500$2.39$94,405.00View SEC Filing  
4/1/2016James George RobinsonDirectorBuy20,500$2.40$49,200.00View SEC Filing  
3/24/2016James George RobinsonDirectorBuy40,000$2.29$91,600.00View SEC Filing  
1/12/2016James George RobinsonDirectorBuy20,000$2.44$48,800.00View SEC Filing  
1/8/2016James George RobinsonDirectorBuy95,000$2.90$275,500.00View SEC Filing  
12/30/2015James George RobinsonDirectorBuy5,000$3.38$16,900.00View SEC Filing  
12/29/2015James George RobinsonDirectorBuy14,000$3.55$49,700.00View SEC Filing  
12/28/2015James George RobinsonDirectorBuy6,000$3.79$22,740.00View SEC Filing  
12/23/2015James George RobinsonDirectorBuy29,854$3.54$105,683.16View SEC Filing  
12/18/2015James George RobinsonDirectorBuy63,334$3.56$225,469.04View SEC Filing  
12/11/2015James George RobinsonDirectorBuy46,812$3.51$164,310.12View SEC Filing  
12/4/2015James George RobinsonDirectorBuy110,000$3.44$378,400.00View SEC Filing  
9/3/2015James George RobinsonDirectorBuy100,000$2.25$225,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Nymox Pharmaceutical Corporation (NASDAQ NYMX)

Source:
DateHeadline
Symposium and Panel Discussion on Nymoxs Fexapotide To Be Held at American Urological AssociationSymposium and Panel Discussion on Nymox's Fexapotide To Be Held at American Urological Association
www.nasdaq.com - November 12 at 11:14 AM
Symposium and Panel Discussion on Nymoxs Fexapotide To Be Held at American Urological Association North ...Symposium and Panel Discussion on Nymox's Fexapotide To Be Held at American Urological Association North ...
globenewswire.com - November 12 at 11:14 AM
Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological ... - NasdaqNymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological ... - Nasdaq
www.nasdaq.com - November 9 at 7:56 AM
Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association ...Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association ...
globenewswire.com - November 7 at 4:34 PM
Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association New York Section Annual Meeting in HavanaNymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association New York Section Annual Meeting in Havana
finance.yahoo.com - November 7 at 4:34 PM
Notable Wednesday Option Activity: ULTI, NYMX, XPO - NasdaqNotable Wednesday Option Activity: ULTI, NYMX, XPO - Nasdaq
www.nasdaq.com - November 2 at 7:11 AM
Nymox Pharmaceutical Corporation (NYMX) Short Interest Down 22.8% in OctoberNymox Pharmaceutical Corporation (NYMX) Short Interest Down 22.8% in October
www.americanbankingnews.com - October 28 at 2:26 AM
Short Interest Drops 22.8% For NYMXShort Interest Drops 22.8% For NYMX
www.thestreet.com - October 27 at 8:53 AM
Nymox Pharmaceutical Corporation (NYMX): How Does It Impact Your Portfolio?Nymox Pharmaceutical Corporation (NYMX): How Does It Impact Your Portfolio?
finance.yahoo.com - October 27 at 8:53 AM
Nymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast ...Nymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast ...
globenewswire.com - October 14 at 6:23 AM
Nymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in SavannahNymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah
finance.yahoo.com - October 14 at 6:23 AM
Nymox Pharmaceutical Corporation (NYMX) Sees Significant Decrease in Short InterestNymox Pharmaceutical Corporation (NYMX) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - October 14 at 1:40 AM
Short Interest Falls 63.6% For NYMXShort Interest Falls 63.6% For NYMX
www.thestreet.com - October 12 at 7:45 AM
Nymox Reports on Symposium and Panel Discussion on Fexapotide at American Urological Association Northeast Sectional ...Nymox Reports on Symposium and Panel Discussion on Fexapotide at American Urological Association Northeast Sectional ...
globenewswire.com - October 11 at 5:52 AM
Nymox Announces October 12 Symposium for Companys BPH Drug at American Urological Association MeetingNymox Announces October 12 Symposium for Company's BPH Drug at American Urological Association Meeting
finance.yahoo.com - October 2 at 7:25 PM
Nymox Pharma (NYMX) Says Its MAA For Fexapotide Triflutate was Validated - StreetInsider.comNymox Pharma (NYMX) Says Its MAA For Fexapotide Triflutate was Validated - StreetInsider.com
www.streetinsider.com - September 15 at 7:03 AM
Nymox Announces New Symposium for Companys BPH Drug at American Urological Association Meeting October 5Nymox Announces New Symposium for Company's BPH Drug at American Urological Association Meeting October 5
finance.yahoo.com - September 15 at 7:03 AM
Nymox Application Validated:Nymox Application Validated:
finance.yahoo.com - September 15 at 7:03 AM
AUA Meeting in Florida September 16 Postponed Due to HurricaneAUA Meeting in Florida September 16 Postponed Due to Hurricane
finance.yahoo.com - September 12 at 7:40 AM
ETFs with exposure to Nymox Pharmaceutical Corp. : September 12, 2017ETFs with exposure to Nymox Pharmaceutical Corp. : September 12, 2017
finance.yahoo.com - September 12 at 7:40 AM
ETFs with exposure to Nymox Pharmaceutical Corp. : August 31, 2017ETFs with exposure to Nymox Pharmaceutical Corp. : August 31, 2017
finance.yahoo.com - September 1 at 6:37 AM
Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 9:32 AM
Nymox Announces Private Placements of $3 MillionNymox Announces Private Placements of $3 Million
finance.yahoo.com - August 10 at 6:23 AM
Nymox Announces Symposium for Companys BPH Drug at ... - NasdaqNymox Announces Symposium for Company's BPH Drug at ... - Nasdaq
www.nasdaq.com - August 8 at 2:39 AM
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Director James George Robinson Acquires 10,000 SharesNymox Pharmaceutical Corporation (NASDAQ:NYMX) Director James George Robinson Acquires 10,000 Shares
www.americanbankingnews.com - August 4 at 9:00 PM
Insider Buying: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Director Buys 5,000 Shares of StockInsider Buying: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Director Buys 5,000 Shares of Stock
www.americanbankingnews.com - August 4 at 9:00 PM
ETFs with exposure to Nymox Pharmaceutical Corp. : August 4, 2017ETFs with exposure to Nymox Pharmaceutical Corp. : August 4, 2017
finance.yahoo.com - August 4 at 6:32 AM
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Director James George Robinson Acquires 15,000 SharesNymox Pharmaceutical Corporation (NASDAQ:NYMX) Director James George Robinson Acquires 15,000 Shares
www.americanbankingnews.com - August 1 at 8:21 PM
Nymox Pharmaceutical Corporation (NYMX) Director James George Robinson Buys 11,500 SharesNymox Pharmaceutical Corporation (NYMX) Director James George Robinson Buys 11,500 Shares
www.americanbankingnews.com - July 7 at 9:03 PM
Nymox Pharmaceutical Corporation (NYMX) Director James George Robinson Acquires 5,000 SharesNymox Pharmaceutical Corporation (NYMX) Director James George Robinson Acquires 5,000 Shares
www.americanbankingnews.com - July 7 at 9:02 PM
Insider Buying: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Director Acquires 3,000 Shares of StockInsider Buying: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Director Acquires 3,000 Shares of Stock
www.americanbankingnews.com - July 7 at 9:02 PM
Commit To Purchase Nymox Pharmaceutical Corp At $3, Earn 25% Using OptionsCommit To Purchase Nymox Pharmaceutical Corp At $3, Earn 25% Using Options
www.thestreet.com - July 6 at 7:37 AM
ETFs with exposure to Nymox Pharmaceutical Corp. : July 4, 2017ETFs with exposure to Nymox Pharmaceutical Corp. : July 4, 2017
finance.yahoo.com - July 5 at 9:08 AM
Sexual Function Improves in First-Line Patients Given Fexapotide Treatment in Nymox U.S. BPH Long-Term Clinical ... - GlobeNewswire (press release)Sexual Function Improves in First-Line Patients Given Fexapotide Treatment in Nymox U.S. BPH Long-Term Clinical ... - GlobeNewswire (press release)
globenewswire.com - May 31 at 11:29 AM
NYMOX Files For Approval of First In Class Prostate Drug in Europe: Teleconference at 4:30 ...NYMOX Files For Approval of First In Class Prostate Drug in Europe: Teleconference at 4:30 ...
globenewswire.com - May 12 at 12:29 AM
NYMOX Files For Approval of First In Class Prostate Drug in Europe: Teleconference at 4:30 EDTNYMOX Files For Approval of First In Class Prostate Drug in Europe: Teleconference at 4:30 EDT
feeds.benzinga.com - May 10 at 11:37 AM
NYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe - GlobeNewswire (press release)NYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe - GlobeNewswire (press release)
globenewswire.com - May 3 at 8:06 PM
BUZZ-US STOCKS ON THE MOVE-Vertex Pharma, Morgan Stanley, F5, Exar, Tonix Pharma, Vertex - NasdaqBUZZ-US STOCKS ON THE MOVE-Vertex Pharma, Morgan Stanley, F5, Exar, Tonix Pharma, Vertex - Nasdaq
www.nasdaq.com - March 29 at 7:38 PM
5 Biohealth Stocks Rising 10% or More on News5 Biohealth Stocks Rising 10% or More on News
247wallst.com - March 1 at 10:26 AM
Nymox Pharmaceuticals (NYMX) Stock Surges on Prostate Drug ProgressNymox Pharmaceuticals (NYMX) Stock Surges on Prostate Drug Progress
www.thestreet.com - March 1 at 10:26 AM
Nymox Pharmaceuticals (NYMX) Stock Surges on Long-Term Prostate Drug Trial SuccessNymox Pharmaceuticals (NYMX) Stock Surges on Long-Term Prostate Drug Trial Success
www.thestreet.com - March 1 at 10:26 AM
Jabbing a Needle in the Overinflated Nymox Prostate Drug HypeJabbing a Needle in the Overinflated Nymox Prostate Drug Hype
www.thestreet.com - March 1 at 10:26 AM
Profile: Nymox Pharmaceutical Corp (NYMX.OQ)Profile: Nymox Pharmaceutical Corp (NYMX.OQ)
www.reuters.com - January 28 at 7:04 PM
Hottest Manufacturing Stocks Now – FOLD AQXP NLNK ACHN - Investorplace.comHottest Manufacturing Stocks Now – FOLD AQXP NLNK ACHN - Investorplace.com
investorplace.com - December 27 at 9:57 AM

Social Media

Financials

Chart

Nymox Pharmaceutical Corporation (NASDAQ NYMX) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.